Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | GRM8 | O00222 | 2/20 | 0.51 |
| ▸ | GRM6 | O15303 | 2/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11840312 | 0.83 | TSHR (0.48) | TDP1GRM8GRM6GRM4TSHR | |
| SCHEMBL6830994 | 0.81 | GRM8 (0.49) | TDP1GRM8GRM6GRM4TSHR | |
| SCHEMBL4481419 | 0.81 | CES1 (0.57) | TDP1TSHRALDH1A1CES1MEN1 | |
| SCHEMBL13527786 | 0.81 | HSD17B10 (0.61) | TDP1GRM8GRM6GRM4ALDH1A1 | |
| SCHEMBL28366694 | 0.80 | SLC1A3 (0.52) | TDP1GRM8GRM6GRM4TSHR | |
| SCHEMBL28362941 | 0.80 | SLC1A3 (0.52) | TDP1GRM8GRM6GRM4TSHR | |
| SCHEMBL5287291 | 0.80 | SLC1A3 (0.52) | TDP1GRM8GRM6GRM4TSHR | |
| SCHEMBL28362981 | 0.80 | SLC1A3 (0.52) | TDP1GRM8GRM6GRM4TSHR | |
| SCHEMBL21176781 | 0.80 | SLC1A3 (0.52) | TDP1GRM8GRM6GRM4TSHR | |
| SCHEMBL18277713 | 0.80 | SLC1A3 (0.52) | TDP1GRM8GRM6GRM4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012167261-A2 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEOINTIMAL STENOSIS | YALE UNIVERSITY (US) | 2012-12-06 | — | — | WO | claimed |
| CN-118561844-A | Cross-linked organic electronic transmission layer material and application thereof | 天合光能股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20170172957-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-2714029-B1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN INC (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2820021-B1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO LTD (KR) | 2016-11-30 | — | — | EP | disclosed |
| US-9481684-B2 | Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2016-11-01 | — | — | US | disclosed |
| US-9415031-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders | ALLERGAN, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150166558-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO., LTD. (KR) | 2015-06-18 | — | — | US | disclosed |
| EP-2820021-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK Chemicals Co., Ltd. (KR) | 2015-01-07 | — | — | EP | disclosed |
| CN-104136441-A | Gonadotropin-releasing hormone receptor antagonists, process for their preparation and pharmaceutical compositions comprising them | SK CHEMICALS CO LTD | 2014-11-05 | — | — | CN | disclosed |
| US-20120329851-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120302621-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. | 2012-11-29 | — | — | US | disclosed |
| EP-2245027-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010117977-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20090110640-A1 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY CONSISTING OF A CYCLIC OLIGOAMID CORE OF 3 TO 4 IDENTICIAL MONOMER UNITS WITH 3 TO 4 PARAMAGNETIC CHELATE SIDE CHAINS | AXELSSON OSKAR | 2009-04-30 | — | — | US | disclosed |
| US-20090110640-A1 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY CONSISTING OF A CYCLIC OLIGOAMID CORE OF 3 TO 4 IDENTICIAL MONOMER UNITS WITH 3 TO 4 PARAMAGNETIC CHELATE SIDE CHAINS | AXELSSON OSKAR | 2009-04-30 | — | — | US | disclosed |
| WO-2007111514-A1 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY CONSISTING OF A CYCLIC OLIGOAMID CORE OF 3 TO 4 IDENTICAL MONOMER UNITS WITH 3 TO 4 PARAMAGNETIC CHELATE SIDE CHAINS | GE HEALTHCARE AS (NO) | 2007-10-04 | — | — | WO | disclosed |
| WO-2003059926-A2 | METHODS AND COMPOSITIONS FOR AMINOACYL-tRNA SYNTHESIS | UNIVERSITY OF MASSACHUSETTS (US) | 2003-07-24 | — | — | WO | disclosed |
| US-5804595-A | ANTIINFLAMMATORY AGENT TO TREAT PAIN CAUSED BY RHEUMATOID ARTHRITIS AND LAPAROSCOPIC SURGERY | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-09-08 | — | — | US | disclosed |
| WO-1997020831-A1 | KAPPA OPIOID RECEPTOR AGONISTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166558-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GNRHR, FSHR, GHRHR | TDP1 3785/4885GRM8 166/4885GRM6 249/4885 |
| US-20090110640-A1 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY CONSISTING OF A CYCLIC OLIGOAMID CORE OF 3 TO 4 IDENTICIAL MONOMER UNITS WITH 3 TO 4 PARAMAGNETIC CHELATE SIDE CHAINS | MLX, PAM, LPXN | TDP1 3535/4885GRM8 1319/4885GRM6 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.